Compare
Myriad Genetics Inc vs QuidelOrtho Corp vs Idexx Laboratories Inc vs Alpha Teknova, Inc.
| Latest fiscal year | Myriad Genetics Inc MYGN | QuidelOrtho Corp QDEL | Idexx Laboratories Inc IDXX | Alpha Teknova, Inc. TKNO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-28 | 2025-12-31 | 2025-12-31 |
| Revenue | $824.50M | $2.73B | $4.30B | $40.52M |
| Revenue growth (YoY) | -1.6% | -1.9% | +10.4% | +7.4% |
| Gross margin | 69.9% | n/a | 61.8% | 33.2% |
| Operating margin | -47.0% | -33.7% | 31.6% | -41.9% |
| Net margin | -44.4% | -41.5% | 24.6% | -42.6% |
| Net income | -$365.90M | -$1.13B | $1.06B | -$17.26M |
| EPS (Diluted) | -$3.95 | -$16.69 | $13.08 | -$0.32 |
| Operating cash flow | $1.80M | $105.20M | $1.18B | -$8.65M |
| Free cash flow | n/a | -$83.00M | $1.06B | -$9.79M |
| Cash & equivalents | $149.60M | $169.80M | $180.07M | $5.91M |
| Total assets | $706.60M | $5.77B | $3.35B | $103.58M |
| Total liabilities | $338.60M | $3.85B | $1.75B | $34.81M |
| Shareholders' equity | $368.00M | $1.92B | $1.61B | $68.78M |
| Return on year-end equity | -99.4% | -58.9% | 66.0% | -25.1% |
| Shares outstanding | 93.50M | 67.90M | 79.71M | 53.56M |
Revenue, most recent five fiscal years
| Fiscal year | Myriad Genetics Inc | QuidelOrtho Corp | Idexx Laboratories Inc | Alpha Teknova, Inc. |
|---|---|---|---|---|
| Latest | $824.50M Ended 2025-12-31 | $2.73B Ended 2025-12-28 | $4.30B Ended 2025-12-31 | $40.52M Ended 2025-12-31 |
| 1 year earlier | $837.60M Ended 2024-12-31 | $2.78B Ended 2024-12-29 | $3.90B Ended 2024-12-31 | $37.74M Ended 2024-12-31 |
| 2 years earlier | $753.20M Ended 2023-12-31 | $3.00B Ended 2023-12-31 | $3.66B Ended 2023-12-31 | $36.68M Ended 2023-12-31 |
| 3 years earlier | $678.40M Ended 2022-12-31 | $3.27B Ended 2023-01-01 | $3.37B Ended 2022-12-31 | $41.42M Ended 2022-12-31 |
| 4 years earlier | $690.60M Ended 2021-12-31 | $1.70B Ended 2022-01-02 | $3.22B Ended 2021-12-31 | $36.89M Ended 2021-12-31 |